Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note: UniQure NV (QURE -$8.08 or -41.72% to $11.33) crashed

June 21, 2023 10:56am

Having unveiled mixed results for its study of a Huntington's disease treatment

A group of patients who received a low dose of the drug, known as AMT-130, showed ONLY functional improvements after two years. The high-dose group showed similar improvements a year following treatment.

Biomarker results were mixed as the high-dose group experienced increases in troublesome proteins a year following treatment. Six patients received the low dose of the Huntington's disease treatment, while 10 received the high dose.

On average, patients in both groups showed improvements in motor skills, functional capacity and total symptoms compared to the expected natural course of Huntington's disease.

The Bottom Line: The low-dose group saw an average decrease of 12.9% after two years. But the high-dose group experienced a 51.5% increase after a year. Those levels seemingly backed off over time, however.

Patients in the low-dose group experienced an 8.1% decrease in this protein after two years. But the high-dose group had a 39.7% increase compared to a jump of 4.7% for the placebo group. <source: Allison Gatlin, IBD>

QURE HAD hopes its gene therapy will be a one-time treatment for Huntington's, a progressive disease that causes nerve cells in the brain to break down and die.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.